Incannex Healthcare Inc. (NasdaqGM:IXHL) is advancing its lead drug candidate IHL-42X for obstructive sleep apnoea (OSA) into late-stage development following successful Phase 2 trials, according to an update from Stonegate Capital Partners. The company reported that both low- and high-dose IHL-42X achieved statistically significant reductions in the Apnoea-Hypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm and 79% in the low-dose arm. Exit interviews showed 57.6% of participants reported perceived improvement in their OSA, with most describing the change as meaningful to daily life, citing better sleep quality, less fatigue, and improved daily functioning. The drug was well tolerated across both dose cohorts, with no serious adverse events and mainly mild, transient treatment-emergent events, reinforcing its potential for broad use if approved.
During the fourth quarter of 2025, Incannex pivoted IHL-42X from pure data generation toward regulatory and late-stage planning. The company is preparing for formal FDA interactions to define the registrational path, including Phase 3 design, primary and secondary endpoints, and potential expedited-review options. These efforts align with Incannex’s 2025 priority to advance IHL-42X into pivotal development while maintaining capital discipline. The company expects to update the market after FDA discussions conclude and the forward development strategy is finalized, positioning IHL-42X for late-stage trials in 2026.
Incannex exited the fourth quarter with a reinforced balance sheet and enhanced flexibility. The company completed a sizeable equity raise, issuing approximately 153.3 million shares for gross proceeds of $69.5 million, bringing cash and cash equivalents to $73.3 million. Management has not used the at-the-market (ATM) facility since August 28, 2025, and the share count has remained unchanged. Additionally, the Board authorized a $20 million share repurchase program, providing a tool to offset dilution and opportunistically return capital while still funding late-stage development, leaving no immediate need for further equity financing.
Beyond IHL-42X, Incannex highlighted highly positive Phase 2 results for PSX-001 (Psi-GAD), its psilocybin-assisted psychotherapy program for generalized anxiety disorder, reinforcing it as a second major value driver. The randomized, placebo-controlled study showed a statistically significant and clinically meaningful mean reduction in HAM-A scores, with 44.1% of treated patients achieving ≥50% response and 27% reaching remission. With an open Investigational New Drug (IND) application, the company is preparing a multi-jurisdiction clinical study and evaluating strategic partnerships to accelerate development and expand global access. Meanwhile, IHL-675A remains in Phase 2 development for rheumatoid arthritis, with ongoing trial-related investment reflected in R&D and tax-incentive activity, and is viewed as a complementary anti-inflammatory platform asset that can broaden Incannex’s long-term commercial opportunity.
Stonegate Capital Partners uses a probability-adjusted Discounted Cash Flow Model when valuing IXHL, returning a valuation range of $1.32 to $1.76 with a midpoint of $1.50 based on a discount rate range of 12.50% to 17.25% and a current risk adjustment range of 13% to 18%. Further details on the model can be found in the full report. The model is highly levered to the out years due to the long-term nature of IXHL's industry, leading to the potential for dramatic re-ratings as new information becomes available.
